Milbemycin Oxime, Praziquantel

Verify with FDA CVM →

1,195 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
1,195
Total Reports
44
Deaths Reported
370.0%
Death Rate

Active Ingredients

Milbemycin Oxime, Praziquantel

Administration Routes

OralUnknownTopicalOther

Species Affected

Dog 1,178
Unknown 15
Human 1
Cat 1

Most Affected Breeds

Retriever - Labrador 164
Crossbred Canine/dog 83
Retriever - Golden 67
Shepherd Dog - German 65
Dog (unknown) 54
Shepherd Dog - Australian 45
Beagle 37
Chihuahua 36
Pit Bull 34
Terrier - Yorkshire 26

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 314
Vomiting 203
Diarrhoea 88
Lack of efficacy (endoparasite) - hookworm 88
Lethargy (see also Central nervous system depression in Neurological) 87
Lack of efficacy (endoparasite) - tapeworm 63
Other abnormal test result NOS 54
Lack of efficacy (endoparasite) - NOS 50
Seizure NOS 47
Lack of efficacy (endoparasite) - roundworm NOS 47
Not eating 43
Loose stool 39

Outcome Breakdown

Outcome Unknown
631 (53.5%)
Recovered/Normal
258 (21.9%)
Ongoing
244 (20.7%)
Died
24 (2.0%)
Euthanized
20 (1.7%)
Recovered with Sequela
3 (0.3%)

Data Summary

Metric Value
Total adverse event reports 1,195
Reports involving death 44
Case-fatality rate (reported events) 370.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Milbemycin Oxime, Praziquantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 1,195 adverse event reports referencing Milbemycin Oxime, Praziquantel, including 44 reports in which the animal died — a 370.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Milbemycin Oxime, Praziquantel. Reported administration routes include Oral, Unknown, Topical, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Milbemycin Oxime, Praziquantel reports are Dog (1,178 reports), Unknown (15 reports), Human (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (164), Crossbred Canine/dog (83), Retriever - Golden (67) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Milbemycin Oxime, Praziquantel are Lack of efficacy (endoparasite) - heartworm (314), Vomiting (203), Diarrhoea (88), Lack of efficacy (endoparasite) - hookworm (88). Of the 1,180 reports with a coded outcome, Outcome Unknown is the leading category at 53.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Milbemycin Oxime, Praziquantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial